Background
==========

Liposarcoma is the most common soft tissue sarcoma, accounting for approximately 20% of all sarcomas in adults \[[@b1-medscimonit-24-7329]\]. The most recent World Health Organization classification of soft tissue tumors recognizes 5 categories of liposarcoma: 1) well-differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; 2) de-differentiated; 3) myxoid; 4) round cell; and 5) pleomorphic \[[@b2-medscimonit-24-7329]\]. Surgery remains the primary treatment for localized liposarcoma, while conventional radiotherapy and cytotoxic chemotherapy are often used to treat metastatic liposarcoma. However, the most common types, well-differentiated liposarcoma and de-differentiated liposarcoma, show obvious resistance to conventional radiotherapy and cytotoxic chemotherapy \[[@b3-medscimonit-24-7329]\].

Liposarcoma subtype is an important determinant of local recurrence and metastatic potential \[[@b4-medscimonit-24-7329]\], but precise prediction of patient outcomes currently remains difficult for individual patients. Previous studies have conducted microarray analysis to explore genes as potential biomarkers for diagnosis, prognosis, or monitoring of curative effects in liposarcoma, and several genes or gene signatures have been identified \[[@b5-medscimonit-24-7329]--[@b7-medscimonit-24-7329]\]. However, these studies have several limitations. For example, some of these studies only examined the function of several potential genes, but did not construct gene networks to find hub genes or estimate the prognostic value of those genes. Other studies merely examined the function of individual genes, but did not construct gene signatures to search for more valuable prognostic indicators. Moreover, the results of some studies have not been validated by other studies.

Previously, Iura et al. \[[@b8-medscimonit-24-7329]\] and Gobble et al. \[[@b9-medscimonit-24-7329]\] investigated the genes that contribute to liposarcomagenesis using microarray analysis methods; however, neither studies performed a gene-gene interaction analysis to identify key genes, nor did they establish a gene signature to predict the prognosis of liposarcoma. Therefore, the exact genes underlying liposarcoma tumorigenesis remain to be elucidated. In this study, we aimed to identify the genes or gene signature associated with the prognosis of liposarcoma patients by re-analyzing the microarray data from Iura et al. \[[@b8-medscimonit-24-7329]\] and Gobble et al. \[[@b9-medscimonit-24-7329]\] studies using bioinformatic analysis methods. We first explored the gene profiles related to liposarcoma pathogenesis and the associated functions and related pathways; then we identified the hub genes of the gene profiles; and finally, we established a gene signature as a new candidate indicator for predicting survival in patients with liposarcoma.

Material and Methods
====================

Microarray data
---------------

The gene expression profiles were downloaded as microarray data from the Gene Expression Omnibus (GEO, *<http://www.ncbi.nlm.nih.gov/geo/>*) database. The liposarcoma-associated dataset GSE59568 \[[@b8-medscimonit-24-7329]\] based on GPL13915 3D-Gene Human Oligo chip 25k V2.1 was downloaded from the GEO database, representing a total of 9 human liposarcoma specimens, including 6 myxoid liposarcoma samples and 3 normal adipose tissue samples. To validate gene markers for use as specific signatures for patients with liposarcoma, liposarcoma data (GSE30929, 140 patients) \[[@b9-medscimonit-24-7329]\] was also downloaded from the database. Approval from an ethics committee was not necessary because the data were freely provided by the GEO database.

Identification of differentially expressed genes (DEGs)
-------------------------------------------------------

The R statistical software (version 3.4.2) and Bioconductor packages were employed to identify differentially expressed genes (DEGs) among liposarcoma samples and normal samples. The probe data were converted into gene expression data before the pro-process analysis. For the case of a gene corresponding to multiple probe data, an average data was calculated and used as the gene expression value \[[@b10-medscimonit-24-7329]\]. Also, genes with over 20% \[[@b11-medscimonit-24-7329]\] missing values were eliminated; otherwise, the data were supplemented with mean values, and the box diagram of the expression value in each sample was drawn before and after pre-processing, then the *t*-tests were applied to analyze the DEGs between the liposarcoma group and normal using the limma package. A DEG was identified when it met the criteria of false discovery rate (FDR) \< 0.05 and \|log fold change C\| (logFC) ≥2.

Gene function annotation and pathway enrichment analysis
--------------------------------------------------------

The gene annotation analysis of DEGs used the DAVID online tool which is freely available (*<https://david.ncifcrf.gov/>*). We analyzed 3 Gene Ontology (GO) categories, including Biological Process (BP), Molecular Function (MF), and Cellular Component (CC). A GO category was considered significant enrichment when the *P* value was less than 0.05. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was also conducted to evaluate the modules at the functional level, and this analysis used the online tool of DAVID. A significant pathway was defined when the *P* value was less than 0.05.

Protein-protein interaction (PPI) network and module analysis
-------------------------------------------------------------

The protein-protein interaction (PPI) network is often used to identity hub genes which are involved in disease pathogenesis at the protein interaction level. In this study, the Search Tool for the Retrieval of Interacting Genes (STRING) online tool (*<http://www.string-db.org/>*) was used to analyze the PPI of DEGs. Cytoscape software (version 3.5) was then used for construction of a PPI network using the data from STRING. Module analysis and GO analysis were then carried out by 2 Cytoscape plug-ins, namely, Molecular Complex Detection (MCODE) and Biological Network Gene Ontology tool (BiNGO), respectively, to illuminate the biological significance of gene modules in liposarcoma.

Construction of distant recurrence-free survival (DRFS) model and receiver operating characteristic curve (ROC) curve
---------------------------------------------------------------------------------------------------------------------

The hub genes from the PPI network were selected as candidate markers and applied to the construction of a distant recurrence-free survival (DRFS) model. We used the linear genes prognostic model to calculate a gene signature prognostic score for 140 patients with liposarcoma based on the survival data from GSE30929. The univariate Cox proportional regression model was applied to identify the hub genes that related to the DRFS, and the significance level was defined if the *P* value was less than 0.05.

A prognostic risk score was developed to predict the DRFS of liposarcoma. This prognostic risk score was based on a linear combination of the gene expression level weighted by the regression coefficient (β) derived from the univariate Cox regression. The formula of calculation of risk score was as followed: risk score=expression of Gene~1~×β~1~Gene~1~+expression of Gene~2~×β~2~Gene~2~+expression of Gene~n~×β~n~Gene~n~ \[[@b12-medscimonit-24-7329]\]. We chose the median values of the risk scores to divide the patients into high risk and low risk groups respectively, then the receiver operating characteristic curve (ROC) to predict the 1-, 3-, and 5-year survival of the patients based on the risk score of the gene signature. We also used the Kaplan-Meier curves to estimate the association of high or low risk scores with the survival of patients. A 2-sided *P* less than 0.05 was regarded as a significantly difference.

Construction of the nomogram
----------------------------

The nomograms for the prediction of the probability of gene signature on liposarcoma were established with the selected independently significant variables, including the significant clinical characteristics, genes and risk scores. The nomograms were visualized by rms package (version 5.1--2) and its auxiliary packages.

Results
=======

Identification of DEGs
----------------------

Based on the DEG selection criteria (\|logFC\| ≥2, with FDR \<0.05), a total of 1111 DEGs between human liposarcoma tissues and normal adipose tissues were identified after pre-processing the raw data from GSE59568 dataset, and a subset comprising 604 significantly downregulated DEGs and 507 significantly upregulated DEGs was selected for subsequent analysis. The distribution of the upregulated and downregulated DEGs is displayed in [Figure 1](#f1-medscimonit-24-7329){ref-type="fig"}.

GO and KEGG pathway enrichment analysis
---------------------------------------

The GO functions of the DEGs showed that the most enriched GO term relevant to BP was response to lipopolysaccharide (GO: 0032496, *P*=3.37E-25), to CC proteinaceous extracellular matrix (GO: 0005578, *P*=1.53E-05), and to MF protease binding (GO: 0002020, *P*=0.001). The KEGG pathway analysis revealed that Cancer Pathways (hsa05200, *P*=0.002) were the most significant pathways of the DEGs. The results are presented in [Figure 2](#f2-medscimonit-24-7329){ref-type="fig"}.

Construction of PPI network and subnetwork analysis
---------------------------------------------------

Based on the results of STRING online tool analysis of the DEGs, a PPI network was constructed by the Cytoscape software, which comprised 312 nodes and 687 edges. Two plug-ins for the Cytoscape software, MCODE and BiNGO, were used to carry out subnetwork analysis. Ten DEGs with high degrees of connectivity were selected as the hub genes in liposarcoma from the PPI network: *PRPL10L*, *RPS3A*, *RPS23*, *RPS3*, *RPL36*, *MCM2*, *WRD12*, *NIP7*, *MRPL3*, *RPL23A*, and MK1671P ([Figure 3A](#f3-medscimonit-24-7329){ref-type="fig"}). The top 3 subnetworks are shown in [Figure 3B--3D](#f3-medscimonit-24-7329){ref-type="fig"}. The GO enrichment analysis of the top 3 subnetworks is shown in [Table 1](#t1-medscimonit-24-7329){ref-type="table"}.

DRFS model and ROC curve analysis
---------------------------------

Because *MKI67IP* was not significantly expressed in the GSE30929 dataset, we did not select it for subsequent analysis. The Cox regression model revealed that only *NIP7*, *RPL10L*, and *MCM2* exhibited significant correlation with DRFS in liposarcoma in the GSE30929 dataset, and the regression coefficients were −0.676, −0.703, and 0.868, respectively ([Table 2](#t2-medscimonit-24-7329){ref-type="table"}). Thus, we chose *NIP7*, *RPL10L*, and *MCM2* to construct the DRFS model. We divided the genes into high and low expression groups according to their median expression. As shown in [Figure 4](#f4-medscimonit-24-7329){ref-type="fig"}, low expression of *MCM2* was associated with a better DRFS in liposarcoma compared with higher expression, while higher expression of *NIP7* and *RPL10L* in liposarcoma correlated with poor DRFS results.

The risk score for each patient was calculated based on the regression coefficient of the 3 genes. By applying the median as the cutoff point, 140 patients with liposarcoma were classified into the high-risk group (n=70) and the low-risk group (n=70). The heatmap shows that the protective genes had high expression in the low-risk group, while the risky genes exhibit high expression in high-risk group ([Figure 5A](#f5-medscimonit-24-7329){ref-type="fig"}). The patients in the high-risk group exhibited significantly worse DRFS than those in the low-risk group ([Figure 5B](#f5-medscimonit-24-7329){ref-type="fig"}). The risk score could largely predict the 1-, 3-, and 5-year DRFS of patients with liposarcoma, as the value of the area under the ROC curve (AUC) was 0.745, 729, and 0.677, respectively ([Figure 5C](#f5-medscimonit-24-7329){ref-type="fig"}).

A nomogram was visualized by rms and its auxiliary packages based on the subtypes of liposarcoma, *MCM2*,*NIP7*,*RPL10L*, and risk scores, and demonstrated that the risk scores contributed the most risk points, whereas the subtypes of liposarcoma and 3 genes contributed much less ([Figure 6](#f6-medscimonit-24-7329){ref-type="fig"}).

Prognostic value analysis for subtypes of liposarcoma
-----------------------------------------------------

The GSE30929 dataset included 5 subtypes of liposarcoma. Hence, we performed subtype analysis on patients with liposarcoma. We found that significantly different survival rates only occurred in the round cell subtype, with a Log-Rank *P*-value of 0.031; subtype AUC analysis revealed the 1- and 3-year AUCs of the myxoid subtype and the 3-year AUC of myxoid/round cell to be over 0.8, indicating a high prognostic value (see [Table 3](#t3-medscimonit-24-7329){ref-type="table"}).

Comparison of the results between microarray data studies and our study
-----------------------------------------------------------------------

Compared with the previous studies that analyzed the gene profile in the liposarcoma using microarray data, our study lacked cell validated experiment and tissue validated experiment, however, we conducted a PPI network analysis gene signature analysis for the DEG, which were not performed in the previous 2 studies (see [Table 4](#t4-medscimonit-24-7329){ref-type="table"}). In addition, we did a validated analysis for a microarray analysis results using another microarray data, which also increased the reliable of our results.

Discussion
==========

Many genes are involved in the tumorigenesis of cancers, and some could serve as critical biomarkers for diagnosis, monitoring therapy, and determining the prognosis of cancers. To date, the molecular mechanism of liposarcoma pathogenesis remains unclear. In addition, there is an imperative need for prognostic factors that can reliable pinpoint the outcomes in patients with liposarcoma \[[@b13-medscimonit-24-7329]\]. Recently, several genomic analyses studies reported a molecular catalogue that significant related to the liposarcoma tumorigenesis and outcome \[[@b14-medscimonit-24-7329]--[@b17-medscimonit-24-7329]\]. Tap et al. \[[@b18-medscimonit-24-7329]\] identified chromosomal and genetic abnormalities in well-differentiated and de-differentiated liposarcoma using an oligonucleotide array-based comparative genomic hybridization approach. Crago et al. \[[@b19-medscimonit-24-7329]\] evaluated the copy number alterations (CNAs) of 55 patients with well-differentiated and 52 patients with de-differentiated liposarcoma using an arrays method. Hoffman et al. \[[@b20-medscimonit-24-7329]\] analyzed patients who presented with localized or metastatic myxoid liposarcoma and found that the receptor tyrosine kinase encoded by the *AXL* gene was a prognosticator of disease-specific survival in univariate analysis. De Cecco et al. \[[@b21-medscimonit-24-7329]\] conducted gene expression profiling and immunohistochemical analyses of specimens of pure myxoid (ML) and pure round cell (RC) liposarcomas and revealed that the *YY1/c-MYC/HDAC2* axis, cell cycle-related *MKNK2*, and stemness-related *MSX1* were involved in maintaining RC variant cells in a fast-cycling and undifferentiated state. These studies indicated that there are several valuable genes or copy numbers that are associated with the genomic complexity of liposarcoma and could be key to the tumorigenesis and prognosis of liposarcoma.

Notably, there is little knowledge about the gene signature and the DRFS in patients with liposarcoma. Gobble et al. \[[@b9-medscimonit-24-7329]\] calculated a risk score for each patient using 588 genes and found that patients with low risk scores had a 3-year DRFS of 83% versus 45% for high risk score patients; they also showed that *TOP2A*, *PTK7*, and *CHEK1* were overexpressed in liposarcoma samples of all 5 subtypes and in liposarcoma cell lines. Saâda-Bouzid et al. \[[@b22-medscimonit-24-7329]\] showed that the amplification of *HMGA2* was associated with the atypical lipomatous tumor/well-differentiated liposarcoma histological type and a good prognosis, whereas *CDK4* and *JUN* amplifications were associated with de-differentiated liposarcoma histology and a bad prognosis. In the present study, to identify the genes crucial to liposarcoma tumorigenesis and define genes significantly related to the prognosis of patients, we conducted comprehensive analysis of 2 microarray datasets. We screened DEGs and identified the associated functions and pathways. We then identified hub genes of the DEGs, which were key to liposarcoma tumorigenesis. Finally, we identified a 3-gene signature, including 1 protective gene (*MCM2*) and 2 risky genes (*NIP7* and *RPL10L*) that could independently predict DRFS in patients with liposarcoma. These results provided deep insights into the mechanism of liposarcoma tumorigenesis.

However, no consistent genes have been verified by previous studies, which could potentially be due, at least in part, to differing detection methods and sample sizes. Compared to the previous studies, our study showed that the expression of 3 genes (*MCM2*, *NIP7*, and *RPL10L*) could act as an independent risk factor for liposarcoma patients. Moreover, the risk score of this 3-gene signature could be an indicator for patients in the clinical setting. In addition, our study examined the prognostic value of the *MCM2-NIP7-RPL10L* signature in subtypes of liposarcoma, and found that the prognostic value of this signature was even better in some subtypes of liposarcoma than in our overall analysis of liposarcoma. Therefore, our results provided a new indicator for the prediction of DRFS in patients with liposarcoma.

The roles of *Nip7*, *RPL10L*, and *MCM2* have been investigated in several studies. Medvedev et al. analyzed the amino acid sequences of the Nip7 proteins from 35 archaeal species to identify positions containing mutations specific to the hydrostatic pressure and temperature of archaeal habitats. They found that adaptation to temperature changes by the Nip7 protein caused more pronounced modifications in sequence and structure than did pressure changes \[[@b23-medscimonit-24-7329]\].

Another study found complexes of molecular masses in the range of 40S--80S. Downregulation of Nip7 affects cell proliferation, which is consistent with an important role for Nip7 in rRNA biosynthesis in human cells \[[@b24-medscimonit-24-7329]\]. However, there is little evidence of any role in the pathogenesis of cancer.

A previous study observed that *RPL10L* deficiency could disturb ribosome biogenesis in late-prophase spermatocytes and prohibit the transition from prophase into metaphase of the first meiotic division, resulting in male infertility \[[@b25-medscimonit-24-7329]\]. *RPL10* is also a tumor suppressor gene, and the protein it encodes is known as the tumor suppression protein QM \[[@b26-medscimonit-24-7329]\]. *RPL10L* was expressed in 76% of a large ovarian tumor panel, 84% in papillary serous cancers, 76% in tumors with mixed histology, and 44% in endometrioid tumors \[[@b27-medscimonit-24-7329]\]. *RPL10L* can also be downregulated by *TMEM9* and is involved in the cell invasion, migration, and adhesion of hepatoma cells \[[@b28-medscimonit-24-7329]\].

*MCM2* has been shown to be overexpressed in many human malignancies, and is an important target for cancer chemotherapy \[[@b29-medscimonit-24-7329]\]. In human malignant fibrous histiocytomas (MFHs), a study observed that *MCM2* expression correlated with cell proliferation rather than apoptosis of MFHs, and that the expression was ubiquitous in proliferating cells, regardless of P53 expression of \[[@b30-medscimonit-24-7329]\]. In a study using radio-hyperthermo-chemotherapy (RHC) to treat sarcomas, researchers found high pre-RHC *MCM2* and high post-RHC growth indices to be significant unfavorable prognostic factors \[[@b31-medscimonit-24-7329]\]. High expression of *MCM2* has also been associated with poor prognosis in primary localized myxofibrosarcomas \[[@b32-medscimonit-24-7329]\].

Although the results of our study could have an important impact on the clinical setting, several limitations to our study should be noted. First, due to the limited number of suitable microarray datasets, we only selected GSE59568 to conduct gene function analysis and identify hub genes and we selected GSE30929 for the prognostic value analysis of gene signatures, which might undermine the robustness of the results. Second, the sample size of GSE59568 was small, with only 6 myxoid liposarcoma samples and 3 normal adipose tissue samples; a larger sample size of liposarcoma tissues with other subtypes of liposarcoma is needed to validate our results. Third, the type of liposarcoma in GSE59568 was myxoid liposarcoma; the dataset lacked other subtypes of liposarcoma. Hence, our results should be confirmed in a study using other subtypes of liposarcoma. Fourth, overall survival time is an important endpoint for patients; however, the GSE30929 dataset only provided DRFS data, which lead to this study merely calculating the risk factors of gene signatures associated with DRFS. Thus, other survival indices, such as overall survival time, should be analyzed in a future study. Fifth, the GSE59568 and GSE30929 data were based on the microarray technique. Thus, the results of this study lack any functional validation; other experimental techniques are needed to verify our findings. Despite these limitations, our current study has identified 1111 DEGs via a whole genome expression level screening and 9 hub genes by using a bioinformatics method. We then constructed a 3-gene DRFS prognostic signature of liposarcoma patients. These findings provide insight into tumorigenesis of liposarcoma and might have a clinical utility for liposarcoma diagnosis and decision-making in liposarcoma management.

Conclusions
===========

This study analyzed the genome-wide gene expression profiles of liposarcoma, identified a gene profile that was crucial to the tumorigenesis of liposarcoma, and identified the hub genes of the gene profile. We also identified a 3-gene-signature, which could serve as a crucial indicator for DRFS of patients with liposarcomas. However, due to the limitations in our study, our findings still need to be verified in large cohort studies, and in studies using cells and animal experiments to validate these findings.
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DEGs

:   differentially expressed genes

GO

:   Gene Ontology

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

DRFS

:   distant recurrence-free survival

ROC

:   receiver operating characteristic curve

FDR

:   false discovery rate

*NIP7*

:   nucleolar pre-rRNA processing protein 7

*RPL10L*

:   ribosomal protein L10 like

*MCM2*

:   minichromosome maintenance complex component 2 (MIM number: 116945)

*RPS3A*

:   ribosomal protein S3A (MIM number: 180478)

*RPL36*

:   ribosomal protein L36

*MRPL3*

:   mitochondrial ribosomal protein L3 (MIM number: 607118)

*TMEM9*

:   transmembrane protein 9 (MIM number: 616877

![Volcano plot shows the distribution of upregulated and downregulated DEGs. The X-axis indicates the fold change and Y-axis indicating the -log10 FDR value. DEGs upregulated with a fold change \>2 and FDR \<0.05 are depicted in red, and those downregulated with a fold change \>2 and FDR \<0.05 are shown in turquoise. DEGs -- differentially expressed genes; FDR -- false discovery rate.](medscimonit-24-7329-g001){#f1-medscimonit-24-7329}

![(**A**) GO enrichment analysis of upregulated DEGs in biological processes; (**B**) KEGG analysis of upregulated DEGs. DEGs -- differentially expressed genes; GO -- Gene Ontology; KEGG -- Kyoto Encyclopedia of Genes and Genomes.](medscimonit-24-7329-g002){#f2-medscimonit-24-7329}

![Module analysis of the PPI network for DEGs using data based on the STRING dataset. (**A**) The PPI network for the total DEGs, and hub genes located at the edge of the PPI network. (**B--D**) Functional submodules of the PPI network analyzed by Cytoscape. DEGs -- differentially expressed genes; PPI -- protein-protein interaction.](medscimonit-24-7329-g003){#f3-medscimonit-24-7329}

![Kaplan-Meier survival curves for liposarcoma patients with high and low expression of mRNA with regard to distant recurrence-free survival. (**A**) MCM2; (**B**) NIP7; (**C**) RPL10L.](medscimonit-24-7329-g004){#f4-medscimonit-24-7329}

![The prognostic performance of the 3-mRNA signature of liposarcoma. (**A**) Patient survival status and time distributed by risk score (upper); risk score curve of the 3-mRNA signature (middle); heatmap of 3-mRNA signature from liposarcoma patients (low). (**B**) The prognostic performance of the risk score shown by the time-dependent receiver operating characteristic (ROC) curve for predicting the 1-, 3-, and 5-year DRFS. (**C**) The Kaplan-Meier test of the risk score for the overall survival. DRFS -- distant recurrence-free survival.](medscimonit-24-7329-g005){#f5-medscimonit-24-7329}

![A nomogram predicting 1-, 3- and 5-year DRFS, and comparing 3 gene-signature with risk score. DRFS, distant recurrence-free survival.](medscimonit-24-7329-g006){#f6-medscimonit-24-7329}

###### 

Enrichment analysis results of the three modules (GO).

  Term           Description                                                           Count   *P* value   Genes
  -------------- --------------------------------------------------------------------- ------- ----------- ---------------------------------------------------------------------------------------------------------
  **Module 1**                                                                                             
  GO: 0003735    Structural constituent of ribosome                                    14      2.47E-25    *MRPL3, RPL36, RPL23A, RPL22L1, RPL39, RPL28, RPS3, RPL10L, RPL32, RPS3A, RPL34, RPL26L1, RPS10, RPS23*
  GO: 0006412    Translation                                                           14      1.51E-24    *MRPL3, RPL36, RPL23A, RPL22L1, RPL39, RPL28, RPS3, RPL10L, RPL32, RPS3A, RPL34, RPL26L1, RPS10, RPS23*
  GO: 0006614    SRP-dependent cotranslational protein targeting to membrane           11      5.20E-21    *RPL32, RPS3A, RPL34, RPL26L1, RPL36, RPS10, RPL23A, RPL39, RPL28, RPS23, RPS3*
  GO: 0019083    Viral transcription                                                   11      3.24E-20    *RPL32, RPS3A, RPL34, RPL26L1, RPL36, RPS10, RPL23A, RPL39, RPL28, RPS23, RPS3*
  GO: 0000184    Nuclear-transcribed mRNA catabolic process, nonsense-mediated decay   11      6.09E-20    *RPL32, RPS3A, RPL34, RPL26L1, RPL36, RPS10, RPL23A, RPL39, RPL28, RPS23, RPS3*
  **Module 2**                                                                                             
  GO: 0006364    rRNA processing                                                       5       8.71E-07    *WDR75, DDX49, BYSL, WDR12, RRP9*
  GO: 0005730    Nucleolus                                                             6       4.41E-06    *WDR75, NIP7, BYSL, WDR12, ZNRD1, RRP9*
  GO: 0044822    Poly(A) RNA binding                                                   6       2.49E-05    *WDR75, DDX49, NIP7, BYSL, BCCIP, RRP9*
  GO: 0005654    Nucleoplasm                                                           6       0.001328    *WDR75, DDX49, BYSL, WDR12, ZNRD1, RRP9*
  GO: 0042273    Ribosomal large subunit biogenesis                                    2       0.010377    *NIP7, WDR12*
  **Module 3**                                                                                             
  GO: 0045211    Postsynaptic membrane                                                 3       7.88E-04    *EPHA4, EPHA7, CLSTN2*
  GO: 0072178    Nephric duct morphogenesis                                            2       0.001191    *EPHA4, EPHA7*
  GO: 0005004    GPI-linked ephrin receptor activity                                   2       0.001658    *EPHA4, EPHA7*
  GO: 0046875    Ephrin receptor binding                                               2       0.006147    *EPHA4, EPHA7*
  GO: 0031594    Neuromuscular junction                                                2       0.012018    *EPHA4, EPHA7*

###### 

Correlation between DRFS and hub gene expression in liposarcoma of GSE30929 dataset.

  Gene     Node degree   Crude HR (95% CI)[\*](#tfn2-medscimonit-24-7329){ref-type="table-fn"}   Crude *P*   Coefficient β[\*\*](#tfn3-medscimonit-24-7329){ref-type="table-fn"}
  -------- ------------- ----------------------------------------------------------------------- ----------- ---------------------------------------------------------------------
  NIP7     24            0.509 (0.281--0.920)                                                    **0.025**   −0.676
  RPS3     24            1.296 (0.734--2.290)                                                    0.371       0.260
  MRPL3    22            1.230 (0.696--2.173)                                                    0.477       0.207
  RPL10L   22            0.495 (0.272--0.900)                                                    **0.021**   −0.703
  RPL23A   22            0.708 (0.401--1.251)                                                    0.235       −0.345
  RPS23    19            0.566 (0.314--1.019)                                                    0.058       −0.569
  RPS3A    19            0.823 (0.465--1.455)                                                    0.502       −0.195
  MCM2     18            2.383 (1.292--4.393)                                                    **0.005**   0.868
  RPL36    18            0.752 (0.423--1.336)                                                    0.331       −0.285
  WDR12    18            1.658 (0.929--2.960)                                                    0.087       0.506

The GSE30929 do not have the MKI67IP expression data;

low gene expression was the reference group;

derived from the univariate Cox proportional hazards regression analysis in PDAC patients.

DRFS -- distant recurrence-free survival.

###### 

Prognostic value analysis of gene-signature for the subtype of liposarcoma.

                        Log-rank P value   1-year AUC^\*^   3-year AUC   5-year AUC
  --------------------- ------------------ ---------------- ------------ ------------
  Well-differentiated   0.227              0.692            0.399        0.567
  Dedifferentiated      0.075              0.655            0.622        0.645
  Round cell            0.031              0.665            0.813        0.813
  Myxoid                0.487              0.920            0.920        0.461
  Pleomorphic           0.449              0.647            0.745        0.433

AUC -- area under the curve.

###### 

Comparison the results between previous study and our study.

                                Iura et al. \[[@b8-medscimonit-24-7329]\]   Gobble et al. \[[@b9-medscimonit-24-7329]\]   Our study
  ----------------------------- ------------------------------------------- --------------------------------------------- -----------
  DEGs identification           Yes                                         Yes                                           Yes
  GO analysis                   No                                          No                                            Yes
  Pathway analysis              No                                          Yes                                           Yes
  PPI network analysis          No                                          No                                            Yes
  Gene signature analysis       No                                          No                                            Yes
  COX regression analysis       No                                          No                                            Yes
  Cell validated experiment     Yes                                         Yes                                           No
  Tissue validated experiment   Yes                                         No                                            No
  Survival analysis             Yes                                         Yes                                           Yes
  Subtype analysis              Yes                                         No                                            Yes

DEGs -- differentially expressed genes; GO -- Gene Ontology; PPI -- Protein--protein interaction.
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